Company Filing History:
2 out of 3 
2 out of 485 
Years Active: 2009-2014
Title: Innovations in Gene Delivery by Cheng-Cheng Huang
Introduction
Cheng-Cheng Huang is an accomplished inventor based in Arlington, VA, with a focus on advancements in gene delivery systems. He holds two patents that showcase his innovative contributions to the field of biotechnology, particularly in the development of targeted therapies for cancer treatment.
Latest Patents
Huang's latest patents include groundbreaking work on antibody fragment-targeted immunoliposomes for systemic gene delivery. One patent describes a targeted vector that enhances gene transfer to human hepatocellular carcinoma (HCC) cells in vitro. This technology utilizes cationic liposomes that are covalently conjugated with the monoclonal antibody AF-20, which recognizes a specific glycoprotein abundantly expressed on HCC and other cancer cells. Quantitative binding analysis demonstrated that these targeted liposomes specifically associate with human HCC cells, leading to a significant increase in gene expression. Another patent focuses on nucleic acid-immunoliposome compositions that are therapeutically useful. These compositions consist of cationic liposomes, a single-chain antibody fragment that binds to transferrin receptors, and nucleic acids encoding wild-type p53. This innovative approach targets cancer cells expressing transferrin receptors, offering potential therapeutic applications for various cancers.
Career Highlights
Cheng-Cheng Huang has made significant strides in his career, working with notable organizations such as Synergene Therapeutics, Inc. and Georgetown University. His work has contributed to the advancement of targeted gene delivery systems, which hold promise for improving cancer treatment outcomes.
Collaborations
Huang has collaborated with esteemed colleagues, including Liang Xin Xu and William Alexander, to further his research and development efforts in the field of biotechnology.
Conclusion
Cheng-Cheng Huang's innovative work in gene delivery systems exemplifies the potential of targeted therapies in cancer treatment. His contributions through patents and collaborations continue to pave the way for advancements in medical biotechnology.